There has been a recent wave of intratumoral approaches particularly for immunooncology (e.g. TLR, Sting, oncolytic viruses) and there are manuscripts in the scientific literature about the technical challenges and possibilities (https://jamanetwork.com/journals/jamanetworkopen/fullarticle...).

So, to your question, yes it is specialized, but not particularly difficult. We have taken great care to leverage the learnings of those experts to minimize the challenges of interpatient variability.

But we will only know for sure if our efforts where sufficient once the human clinical data comes back. For now I can say that our preclinical studies are highly encouraging.